Skip to main content
. Author manuscript; available in PMC: 2021 May 31.
Published in final edited form as: Cancer Prev Res (Phila). 2019 Nov 26;13(1):91–100. doi: 10.1158/1940-6207.CAPR-19-0296

Table 2.

Urinary MHBMA and DHBMA concentrations in smokers treated with PEITC and placebo.

Geometric means
Urinary biomarkersa Placebo PEITC % Difference (95% CI) P-valueb
MHBMA (ng/mg Cr) 11.0 12.3 11.13 (−4.2, 28.9) 0.17
DHBMA (ng/mg Cr) 572.9 593.8 3.7 (−10.9, 20.6) 0.64
a

Urinary biomarkers were adjusted for creatinine and batch, and log-transformed.

b

Two-sided p-values were from mixed models that test the PEITC treatment effect, after adjusting for creatinine-adjusted TNE